Nchi: Singapoo
Lugha: Kiingereza
Chanzo: HSA (Health Sciences Authority)
STREPTOKINASE
UNITED ITALIAN TRADING CORPORATION (PRIVATE) LIMITED
B01AD01
1500000 iu/vial
INJECTION, POWDER, FOR SOLUTION
INTRAVENOUS
Prescription Only
CSL BEHRING GMBH
1988-04-30
CSL BEHRING STREPTASE® 1 500 000 PI/CORE/ENGLISH, REV.: 02-JAN-2007 / CSL BEHRING CSL Behring Page 1 of 11 Streptase for Injection 1500000IU per vial PI PACKAGE INSERT Dear Patient, This leaflet gives you important information about this medicine. It is continually updated. Therefore, PLEASE READ THIS LEAFLET CAREFULLY. Unfortunately, one cannot explain all the medical knowledge relating to your disease in such a small leaflet. This is why you might not understand every part of it without a comprehensive medical background or a personal explanation from your doctor. For this reason this leaflet also provides specialized information for your doctor, so that he can help you to understand. If you have further questions about this medicine or any questions about your disease, please ask your doctor or pharmacist. STREPTASE ® 1 500 000 ACTIVE INGREDIENT: Stabilized pure streptokinase, derived from the culture filtrate of beta- haemolytic streptococci of Lancefield group C. It is presented as a white powder and contains stabilizers. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE INGREDIENTS 1 injection vial with 147 to 192 mg dried substance contains 1 500 000 IU streptokinase. OTHER INGREDIENTS Human albumin, sodium-L-hydrogen glutamate monohydrate, polygeline PHARMACEUTICAL FORM AND PRESENTATIONS PHARMACEUTICAL FORM Powder for intravenous or intraarterial administration after reconstitution with physiological saline. PRESENTATIONS Streptase 1 500 000 1 vial of 1 500 000 IU streptokinase PHARMACOTHERAPEUTIC GROUP Streptokinase (antithrombotic agents, enzymes) ATC-code: B01A D01 CSL BEHRING STREPTASE® 1 500 000 PI/CORE/ENGLISH, REV.: 02-JAN-2007 / CSL BEHRING CSL Behring Page 2 of 11 Strept Soma hati kamili